Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings
Rhea-AI Filing Summary
Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction. Following this trade, he directly holds 1,343,886 Ordinary Shares. The filing also lists several existing stock option awards over Ordinary Shares at exercise prices ranging from $1.29 to $54.32 with expirations between 2027 and 2035; per the footnotes, these option rows reflect holdings only and no new transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 460,000 shares
Net Buy
11 txns
Insider
RECANATI LEON
Role
Director
Bought
460,000 shs ($292K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares | 460,000 | $0.635 | $292K |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1, F2 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 1,343,886 shares (Direct);
Stock Option (right to buy) — 10,950 shares (Direct)
Footnotes (2)
- F1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F2. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested by the one-year anniversary of the August 18, 2025 grant date.
Key Figures
Shares purchased: 460,000 Ordinary Shares
Purchase price: $0.635 per share
Shares owned after transaction: 1,343,886 Ordinary Shares
+4 more
7 metrics
Shares purchased
460,000 Ordinary Shares
Non-derivative purchase on August 11, 2026
Purchase price
$0.635 per share
Price for 460,000 Ordinary Shares purchased
Shares owned after transaction
1,343,886 Ordinary Shares
Direct ownership following the reported purchase
Highest option exercise price
$54.3200
Stock option over 250 Ordinary Shares expiring May 16, 2027
Lowest option exercise price
$1.2900
Stock option over 2,500 Ordinary Shares expiring August 18, 2035
Representative option tranche size
1,800 underlying Ordinary Shares
Several option grants with 1,800 underlying shares each
Latest option grant vesting rate
25% per quarter
Options granted August 18, 2025 vest equally each quarter over one year
Key Terms
Ordinary Shares, Stock Option (right to buy), exercise price, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"Stock Option (right to buy) over Evogene Ordinary Shares"
exercise price financial
"stock options with exercise prices from $1.29 to $54.32"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"option expirations between 2027 and 2035"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest equally on a quarterly basis financial
"options vest equally on a quarterly basis (25% per quarter)"
FAQ
What did Evogene (EVGN) director Leon Recanati report in this Form 4?
Leon Recanati reported a purchase of 460,000 Evogene Ordinary Shares at $0.635 per share. After this transaction, he directly holds 1,343,886 Ordinary Shares, according to the Form 4 filing.
What stock options for Evogene (EVGN) does Leon Recanati hold according to this filing?
The filing lists multiple stock options (rights to buy) over Evogene Ordinary Shares, with exercise prices from $1.29 to $54.32 and expirations between 2027 and 2035. Footnotes state these rows reflect existing holdings only, not new transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
